OMass Therapeutics Signs Exclusive Collaboration and Licence Agreement with Genentech for Inflammatory Bowel Disease Therapies
Wednesday, September 03, 2025
OMass Therapeutics has entered into an exclusive collaboration and licence agreement with Genentech, part of the Roche Group, to develop and commercialise its preclinical oral small molecule programme for inflammatory bowel disease (IBD).
As part of the deal, OMass will receive an upfront payment of $20 million and could earn more than $400 million in additional milestone payments linked to preclinical, development, commercial and sales achievements. The company will also be eligible for tiered royalties on future net sales.
Under the agreement, OMass will lead early-stage preclinical development up to candidate selection. Genentech will then take responsibility for clinical trials, regulatory approvals, manufacturing and commercialisation.
The partnership combines OMass’ OdyssION™ platform with Genentech’s established expertise in immunology, aiming to advance new treatment options for the millions of people worldwide affected by IBD.
Source: globenewswire.com
